CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Atezolizumabdrug
Likely dose
Atezolizumab 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04710498
NCT04710498Phase 2Completed
CompareCT.gov

ML42362: Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma

Stanford University·interventional·Posted Jan 14, 2021·Updated Feb 3, 2025

In Brief

A Phase 2 clinical trial evaluating Atezolizumab for Cutaneous Squamous Cell Carcinoma. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The purpose of this research is to evaluate whether the administration of atezolizumab before surgical resection of the tumor is feasible and to evaluate the treatment response, safety, and tolerability of atezolizumab.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCutaneous Squamous Cell Carcinoma
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedJan 14, 2021
Enrollment StartJun 22, 2021
Primary CompletionFeb 7, 2024
Study CompletionFeb 15, 2024
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 5.5 years ago

Interventions

Atezolizumabdrug

Atezolizumab administered intravenous (IV) infusion at a fixed dose of 1200 mg